Grace Therapeutics Schedules FDA Meeting for GTx-104 Resubmission, Reports 12-Month Cash Runway
Summary
Grace Therapeutics announced a scheduled Type A meeting with the FDA to clarify the path for its GTx-104 drug resubmission, alongside reporting a 12-month cash runway and improved fiscal year 2026 financial results.
Key Events
-
FDA Type A Meeting Scheduled for GTx-104
A Type A meeting has been scheduled with the FDA to clarify the path forward for the GTx-104 NDA resubmission, following the Complete Response Letter (CRL) issued in April 2026. The CRL cited non-clinical and manufacturing issues, with no clinical deficiencies identified.
-
12-Month Cash Runway Confirmed
The company reported $17.0 million in cash and cash equivalents as of March 31, 2026, and believes this is sufficient to sustain planned operations for at least 12 months, addressing immediate liquidity concerns.
-
Improved Fiscal Year 2026 Financials
Grace Therapeutics reported a reduced net loss of $7.8 million, or $0.47 per share, for the fiscal year ended March 31, 2026, an improvement from a $9.6 million net loss ($0.79 per share) in the prior year.
-
New Patent Extends GTx-104 Protection
A new U.S. Patent (No. 12,414,943) was issued, covering the IV dosing regimen for GTx-104 and extending intellectual property protection for the drug to 2043.
Analysis
This filing provides critical updates following the FDA's Complete Response Letter (CRL) for GTx-104 and the recent 10-K filing which included a going concern warning. The scheduled Type A meeting with the FDA offers a concrete path to address the non-clinical issues cited in the CRL, with the company expressing confidence in a resubmission. Crucially, the company's declaration of a 12-month cash runway directly addresses immediate liquidity concerns raised by the going concern warning, providing a temporary reprieve and stability. The improved financial results and new patent further support the company's efforts to navigate its challenges.
At the time of this filing, GRCE was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.4M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.